0001193125-22-281955.txt : 20221110 0001193125-22-281955.hdr.sgml : 20221110 20221110073101 ACCESSION NUMBER: 0001193125-22-281955 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20221108 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20221110 DATE AS OF CHANGE: 20221110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Seagen Inc. CENTRAL INDEX KEY: 0001060736 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 911874389 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-32405 FILM NUMBER: 221374952 BUSINESS ADDRESS: STREET 1: 21823 30TH DRIVE SE STREET 2: SUITE CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4255274000 MAIL ADDRESS: STREET 1: 21823 30TH DRIVE SE STREET 2: SUITE CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: SEATTLE GENETICS INC /WA DATE OF NAME CHANGE: 20001116 8-K 1 d744501d8k.htm 8-K 8-K
false 0001060736 0001060736 2022-11-08 2022-11-08

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 8, 2022

 

 

Seagen Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   0-32405   91-1874389

(State or other jurisdiction

of incorporation or organization)

  

(Commission

File Number)

  

(I.R.S Employer

Identification No.)

21823 30th Drive SE

Bothell, Washington 98021

(Address of principal executive offices, including zip code)

(425) 527-4000

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001   SGEN   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

 

 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Appointment of Chief Executive Officer and Class II Director; Employment Agreement with Chief Executive Officer

On November 8, 2022, the Board of Directors (the “Board”) of Seagen Inc. (the “Company”) appointed David R. Epstein as the Chief Executive Officer of the Company and as a member of the Board, in each case effective as of November 9, 2022 (the “Start Date”). Mr. Epstein will serve as a Class II director for a term expiring at the 2024 annual meeting of the Company’s stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal. On the Start Date, Mr. Epstein assumed the duties and responsibilities of the Company’s principal executive officer from Roger D. Dansey, M.D., who was serving as the Interim Chief Executive Officer of the Company since May 5, 2022 until the Start Date. There is no arrangement or understanding with any person pursuant to which Mr. Epstein was appointed as the Chief Executive Officer of the Company and/or as a member of the Board.

Mr. Epstein, age 61, most recently served as an executive partner at Flagship Pioneering from January 2017 to October 2022. From January 2010 to July 2016, he served as Chief Executive Officer of Novartis Pharmaceuticals, a division of Novartis AG. Previously, Mr. Epstein started and led Novartis’ Oncology and Molecular Diagnostic units. Mr. Epstein has extensive public and private company board experience, and currently serves on the board of directors of Evelo Biosciences, Inc. (Nasdaq: EVLO), OPY Acquisition Corp. I (Nasdaq: OHAA) and Senti Biosciences, Inc. (Nasdaq: SNTI). Mr. Epstein previously served as Chairman of the board of directors of Evelo Biosciences, Inc. from September 2019 to June 2022. He also previously served as Chairman and as a member of the board of directors of Axcella Health Inc. (Nasdaq: AXLA) from December 2017 to October 2022 and of Rubius Therapeutics, Inc. (Nasdaq: RUBY) from January 2017 to October 2022. Mr. Epstein also served on the board of International Flavors and Fragrances (NYSE: IFF) from January 2016 to January 2021. Mr. Epstein holds a B.S. Degree in Pharmacy from Rutgers University College of Pharmacy and an M.B.A. in Finance and Marketing from the Columbia University Graduate School of Business.

On November 8, 2022, the Company entered into an employment agreement (the “Epstein Employment Agreement”) with Mr. Epstein in connection with his employment as the Chief Executive Officer of the Company commencing on the Start Date. Pursuant to the Epstein Employment Agreement, while employed as Chief Executive Officer, Mr. Epstein will be eligible for the following compensation and benefits: (i) an initial annual base salary of $1,500,000, (ii) a target annual incentive opportunity under the Company’s executive bonus plan (the “Bonus Plan”) equal to 150% of his annual base salary, (iii) a one-time sign-on award of time-based vesting restricted stock units (the “Epstein RSU Award”) granted pursuant to the terms of the Company’s Amended and Restated 2007 Equity Incentive Plan (the “Plan”) with a target value of $14,000,000, (iv) a one-time sign-on award of time-based vesting options to purchase shares of common stock of the Company (“Common Stock”) with a target value of $14,000,000 (the “Epstein Option Award”) granted pursuant to the Plan, (v) a one-time sign-on award of performance-based options in respect of 400,000 shares of Common Stock (the “Epstein Performance Option Award”) granted pursuant to the Plan, (vi) a one-time relocation payment in the amount of $6,000,000 (payable upon the time Mr. Epstein and his family establish primary residence in the Seattle, Washington area, provided such relocation occurs prior to September 1, 2023, and subject to pro-rated repayment upon certain events prior to the sixth anniversary of the relocation payment), and (vii) certain relocation and temporary living cost benefits. For more information on the Bonus Plan, see “Compensation Discussion and Analysis—Compensation-Setting Process—Cash Incentive Awards” in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on March 30, 2022. The actual number of shares underlying the Epstein RSU Award (107,389) was calculated by dividing the target value of the Epstein RSU Award by the average closing stock price during the 30 calendar days preceding the Start Date. The actual number of shares underlying the Epstein Option Award (243,347) was calculated based on the average closing stock price during the 30 calendar days preceding the Start Date and using a Black Scholes methodology for stock option valuation. The Epstein RSU Award will vest annually over four years beginning on the first anniversary of the Start Date, subject to Mr. Epstein’s continued employment with the Company. Twenty-five percent of the Epstein Option Award will vest on the first anniversary of Start Date and 1/48th of the Epstein Option Award will vest in equal monthly installments thereafter until fully vested on the fourth anniversary of Start Date, subject to Mr. Epstein’s continued employment with the Company. The Epstein Performance Option Award will be subject to performance vesting in tranches tied to Common Stock price targets and each such tranche will time-vest 1/3 on the date of performance vesting, 1/3 on the nine month anniversary of performance-vesting and 1/3 on the 18 month anniversary of performance vesting, in each case, subject to continued employment by the Company. Any unearned portion of the Epstein Performance Option Award will generally be forfeited if the performance vesting conditions are not met on the earlier of (1) December 31, 2028 and (2) a change of control (as defined in the Epstein Employment Agreement).

Under the terms of the Epstein Employment Agreement, in the event of a termination of Mr. Epstein’s employment by the Company without “cause” or due to a “constructive termination” and not in the three months prior to or 18 months following a change of control of the Company, Mr. Epstein will be entitled to receive: (i) payment of severance benefits equal to his annual base salary for 18 months and 1.5 times his target bonus, to be increased to up to 24 months of annual base salary and 2 times target bonus, based on years of service; (ii) payment of 18 months of COBRA premiums, (iii) accelerated time-vesting of 18 months (to be increased to up to 24 months based on length of service) of any unvested equity awards held by Mr. Epstein (including options, RSUs and any earned performance options), and (iv) a minimum of 18 months (to be increased to up to 24 months based on length of service) extended option exercisability for vested outstanding options. In the event of a termination of Mr. Epstein’s employment by the Company without “cause” or due to a “constructive termination” and in the three months prior to or 18 months following a change of control of the Company, Mr. Epstein will be entitled to receive: (i) payment of severance benefits equal to his annual base salary for 36 months and 3 times his target bonus; (ii) payment of 18 months of COBRA premiums, (iii) double-trigger acceleration of equity awards, provided that the Epstein Performance Option Award shall be earned based on the stock price achieved in the change of control and (v) any clawback provisions on the relocation payment will be voided.

The foregoing description of the Epstein Employment Agreement is only a summary and is qualified in its entirety by the terms of the Epstein Employment Agreement, a copy of which will be filed as an exhibit to the Company’s annual report on Form 10-K for the fiscal year ending December 31, 2022.

The Company also entered into it standard form of indemnification agreement (the “Indemnification Agreement”) with Mr. Epstein, which will require the Company, under the circumstances and to the extent provided for therein, to indemnify Mr. Epstein to the fullest extent permitted by law against certain expenses and other amounts incurred by Mr. Epstein as a result of being made a party or threatened to be made a party to certain actions, suits or proceedings by reason of his position as a director, officer, employee or other agent of the Company. The foregoing is only a brief description of the Indemnification Agreement, does not purport to be complete, and is qualified in its entirety by reference to the form of Indemnification Agreement previously filed by the Company as Exhibit 10.29 to the Company’s Registration Statement on Form S-1/A (File No. 333-50266), filed with the Securities and Exchange Commission on January 4, 2001.

There is no family relationship between Mr. Epstein and any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer of the Company.

Amended Employment Agreement with President, Research and Development and Chief Medical Officer

Dr. Dansey has served as Interim Chief Executive Officer of the Company since May 5, 2022 and as the Company’s Chief Medical Officer since May 2018. On November 8, 2022, the Company entered into an amended and restated employment agreement (the “Dansey Employment Agreement”) with Dr. Dansey in connection with his employment as President, Research and Development of the Company, commencing November 9, 2022. Dr. Dansey will also continue to serve as Chief Medical Officer of the Company.

Pursuant to the Dansey Employment Agreement, while employed as President, Research and Development, Dr. Dansey will be eligible for the following compensation and benefits: (i) an initial annual base salary of $1,100,000, (ii) a target annual incentive opportunity under the Bonus Plan equal to 110% of his annual base salary and (iii) a one-time award of performance-based options in respect of 275,000 shares of Common Stock granted pursuant to the Plan (the “Dansey Performance Option Award”). The Dansey Performance Option Award will be subject to performance vesting in tranches tied to Common Stock price targets and each such tranche will time-vest 1/3 on the date of performance vesting, 1/3 on the nine month anniversary of performance-vesting and 1/3 on the 18 month anniversary of performance vesting, in each case, subject to continued employment by the Company. Any unearned portion of the Dansey Performance Option Award will generally be forfeited if the performance vesting conditions are not met on the earlier of (1) December 31, 2028 and (2) a change of control (as defined in the Dansey Employment Agreement).

Under the terms of the Dansey Employment Agreement, in the event of a termination of Dr. Dansey’s employment by the Company without “cause” or due to a “constructive termination” and not in the three months prior to or 18 months following a change of control of the Company, Dr. Dansey will be entitled to receive: (i) payment of

severance benefits equal to his annual base salary for 18 months and 1.5 times his target bonus; (ii) payment of 18 months of COBRA premiums, (iii) accelerated time-vesting of 18 months of any unvested equity awards held by Dr. Dansey, and (iv) 18 months extended option exercisability for vested outstanding options. In the event of a termination of Dr. Dansey’s employment by the Company without “cause” or due to a “constructive termination” and within the three months prior to or 18 months following a change of control of the Company, Dr. Dansey will be entitled to receive: (i) payment of severance benefits equal to his annual base salary for 24 months and 2 times his target bonus; (ii) payment of 18 months of COBRA premiums, (iii) double-trigger acceleration of equity awards, provided that the Dansey Performance Option Award shall be earned based on the stock price achieved in the change of control.

The foregoing description of the Dansey Employment Agreement is only a summary and is qualified in its entirety by the terms of the Dansey Employment Agreement, a copy of which will be filed as an exhibit to the Company’s annual report on Form 10-K for the fiscal year ending December 31, 2022.

Appointment of Sandra M. Swain, M.D. as Class III Director

On November 8, 2022, the Board appointed Sandra M. Swain, M.D. to the Board, effective November 9, 2022. Dr. Swain will serve as a Class III director for a term expiring at the 2025 annual meeting of the Company’s stockholders and until her successor has been duly elected and qualified, or until her earlier death, resignation or removal. There is no arrangement or understanding with any person pursuant to which Dr. Swain was appointed as a member of the Board.

In accordance with the Company’s compensation policy with respect to annual cash fees for non-employee directors, Dr. Swain will receive an annual cash retainer of $60,000 for her service on the Board, which will be prorated during 2022.

In addition, effective as of November 9, 2022 (the “Grant Date”), in accordance with the Company’s policy with respect to initial equity grants to new non-employee directors, the Board granted Dr. Swain a nonstatutory stock option to purchase shares of Common Stock with a target value of $101,370 (the pro rata portion of the Company’s annual non-employee director option grant) (the “Swain Option”) and a restricted stock unit award covering shares of Common Stock with a target value of $101,370 (the pro rata portion of the Company’s annual non-employee director restricted stock unit grant) (the “Swain RSU Award”) pursuant to the terms of the Plan. The actual number of shares underlying the Swain Option (1,763) was calculated based on an approximation of the target award value based on the average closing stock price during the 30 calendar days preceding the Grant Date and using a Black Scholes methodology for stock option valuation. The actual number of shares underlying the Swain RSU Award (778) was calculated by dividing the target value of the Swain RSU Award by the average closing stock price during the 30 calendar days preceding the Grant Date. The Swain Option and the Swain RSU Award will vest in full on the first anniversary of the Grant Date.

The Company also intends to enter into its standard form of Indemnification Agreement with Dr. Swain, which will require the Company, under the circumstances and to the extent provided for therein, to indemnify Dr. Swain to the fullest extent permitted by law against certain expenses and other amounts incurred by Dr. Swain as a result of being made a party or threatened to be made a party to certain actions, suits or proceedings by reason of her position as a director of the Company. The foregoing is only a brief description of the Indemnification Agreement, does not purport to be complete, and is qualified in its entirety by reference to the form of Indemnification Agreement previously filed by the Company as Exhibit 10.29 to the Company’s Registration Statement on Form S-1/A (File No. 333-50266), filed with the Securities and Exchange Commission on January 4, 2001.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    SEAGEN INC.
Date: November 10, 2022     By:  

/s/ Jean I. Liu

      Jean I. Liu
      Chief Legal Officer
 EX-101.SCH 2 sgen-20221108.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 sgen-20221108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 sgen-20221108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Nov. 08, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001060736
Document Type 8-K
Document Period End Date Nov. 08, 2022
Entity Registrant Name Seagen Inc.
Entity Incorporation State Country Code DE
Entity File Number 0-32405
Entity Tax Identification Number 91-1874389
Entity Address, Address Line One 21823 30th Drive SE
Entity Address, City or Town Bothell
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98021
City Area Code (425)
Local Phone Number 527-4000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001
Trading Symbol SGEN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 d744501d8k_htm.xml IDEA: XBRL DOCUMENT 0001060736 2022-11-08 2022-11-08 false 0001060736 8-K 2022-11-08 Seagen Inc. DE 0-32405 91-1874389 21823 30th Drive SE Bothell WA 98021 (425) 527-4000 false false false false Common Stock, par value $0.001 SGEN NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d744501d8k.htm sgen-20221108.xsd sgen-20221108_lab.xml sgen-20221108_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d744501d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d744501d8k.htm" ] }, "labelLink": { "local": [ "sgen-20221108_lab.xml" ] }, "presentationLink": { "local": [ "sgen-20221108_pre.xml" ] }, "schema": { "local": [ "sgen-20221108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sgen", "nsuri": "http://www.seattlegenetics.com/20221108", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d744501d8k.htm", "contextRef": "duration_2022-11-08_to_2022-11-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d744501d8k.htm", "contextRef": "duration_2022-11-08_to_2022-11-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.seattlegenetics.com//20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001193125-22-281955-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-281955-xbrl.zip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